QTTB ▼ -0.5% - Q32 Bio Inc. $QTTB - Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026 Q32 Bio fell 0.5% today following its announcement of an upcoming late-breaking presentation of SIGNAL-AA trial results for bempikibart in alopecia areata at the European Academy of Dermatology and Venereology Congress in 2026. The modest decline suggests investors may be taking profits ahead of the presentation or may have preferred more immediate clinical data rather than an announcement of a future one. 21-SEP-2026 09:16 AM ET